Cargando…

Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART

Commencement of antiretroviral treatment (ART) in severely immunosuppressed HIV-infected persons is associated with unmasking of subclinical disease. The subset of patients that are diagnosed with tuberculosis (TB) disease while on ART have been classified as ART-associated TB. Few studies have repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Worodria, William, Massinga-Loembe, Marguerite, Mayanja-Kizza, Harriet, Namaganda, Jane, Kambugu, Andrew, Manabe, Yukari C., Kestens, Luc, Colebunders, Robert
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004409/
https://www.ncbi.nlm.nih.gov/pubmed/21197091
http://dx.doi.org/10.1155/2011/758350
_version_ 1782193977688064000
author Worodria, William
Massinga-Loembe, Marguerite
Mayanja-Kizza, Harriet
Namaganda, Jane
Kambugu, Andrew
Manabe, Yukari C.
Kestens, Luc
Colebunders, Robert
author_facet Worodria, William
Massinga-Loembe, Marguerite
Mayanja-Kizza, Harriet
Namaganda, Jane
Kambugu, Andrew
Manabe, Yukari C.
Kestens, Luc
Colebunders, Robert
author_sort Worodria, William
collection PubMed
description Commencement of antiretroviral treatment (ART) in severely immunosuppressed HIV-infected persons is associated with unmasking of subclinical disease. The subset of patients that are diagnosed with tuberculosis (TB) disease while on ART have been classified as ART-associated TB. Few studies have reported the incidence of ART-associated TB and unmasking TB-IRIS according to the International Network for the Study of HIV-Associated IRIS (INSHI) consensus definition. To determine the incidence and predictors of ART-associated TB, we screened 219 patients commencing ART at the Infectious Diseases Clinic in Kampala, Uganda for TB by symptoms, sputum microscopy, and chest X-rays and followed them for one year. Fourteen (6.4%) patients were diagnosed with TB during followup. Eight (3.8%) patients had ART-associated TB (incidence rate of 4.3 per 100 person years); of these, three patients fulfilled INSHI criteria for unmasking TB-associated IRIS (incidence rate of 1.6 per 100 person years). A body mass index of less than 18.5 kg/m(2) BMI (HR 5.85 95% CI 1.24–27.46, P = .025) and a C-reactive protein greater than 5 mg/L (HR 8.23 95% CI 1.36–38.33, P = .020) were risk factors for ART-associated TB at multivariate analysis. In conclusion, with systematic TB screening (including culture and chest X-ray), the incidence of ART-associated TB is relatively low in settings with high HIV and TB prevalence.
format Text
id pubmed-3004409
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30044092010-12-30 Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART Worodria, William Massinga-Loembe, Marguerite Mayanja-Kizza, Harriet Namaganda, Jane Kambugu, Andrew Manabe, Yukari C. Kestens, Luc Colebunders, Robert Clin Dev Immunol Research Article Commencement of antiretroviral treatment (ART) in severely immunosuppressed HIV-infected persons is associated with unmasking of subclinical disease. The subset of patients that are diagnosed with tuberculosis (TB) disease while on ART have been classified as ART-associated TB. Few studies have reported the incidence of ART-associated TB and unmasking TB-IRIS according to the International Network for the Study of HIV-Associated IRIS (INSHI) consensus definition. To determine the incidence and predictors of ART-associated TB, we screened 219 patients commencing ART at the Infectious Diseases Clinic in Kampala, Uganda for TB by symptoms, sputum microscopy, and chest X-rays and followed them for one year. Fourteen (6.4%) patients were diagnosed with TB during followup. Eight (3.8%) patients had ART-associated TB (incidence rate of 4.3 per 100 person years); of these, three patients fulfilled INSHI criteria for unmasking TB-associated IRIS (incidence rate of 1.6 per 100 person years). A body mass index of less than 18.5 kg/m(2) BMI (HR 5.85 95% CI 1.24–27.46, P = .025) and a C-reactive protein greater than 5 mg/L (HR 8.23 95% CI 1.36–38.33, P = .020) were risk factors for ART-associated TB at multivariate analysis. In conclusion, with systematic TB screening (including culture and chest X-ray), the incidence of ART-associated TB is relatively low in settings with high HIV and TB prevalence. Hindawi Publishing Corporation 2011 2010-12-08 /pmc/articles/PMC3004409/ /pubmed/21197091 http://dx.doi.org/10.1155/2011/758350 Text en Copyright © 2011 William Worodria et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Worodria, William
Massinga-Loembe, Marguerite
Mayanja-Kizza, Harriet
Namaganda, Jane
Kambugu, Andrew
Manabe, Yukari C.
Kestens, Luc
Colebunders, Robert
Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
title Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
title_full Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
title_fullStr Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
title_full_unstemmed Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
title_short Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
title_sort antiretroviral treatment-associated tuberculosis in a prospective cohort of hiv-infected patients starting art
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004409/
https://www.ncbi.nlm.nih.gov/pubmed/21197091
http://dx.doi.org/10.1155/2011/758350
work_keys_str_mv AT worodriawilliam antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT massingaloembemarguerite antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT mayanjakizzaharriet antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT namagandajane antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT kambuguandrew antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT manabeyukaric antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT kestensluc antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart
AT colebundersrobert antiretroviraltreatmentassociatedtuberculosisinaprospectivecohortofhivinfectedpatientsstartingart